Estrogen
Estrogen has been studied in 558 papers since 1980: 13 trials and 105 observational studies in people, 70 in animals, 5 in cells, 355 reviews; 196 in the past year. The newest paper, Nov 16, 2026: “Hormonal Therapy for Osteoporosis: Mechanisms, Trial Evidence, and Current Place in Fracture Prevention”.
Research on it is growing 42% faster than aging research as a whole: 145 papers in the latest year counted
194 new papers in 30 daysSee all 3,690 papers on estrogen
At a glance
Mouse studies report lower oxidative stress with estrogen, reproduced by independent labs; one study reports improved muscle calcium entry in aging male mice. A human cohort links oral estrogen alone during menopause with higher dementia risk, while human mortality associations point both ways. Some papers declare ties to companies including Bayer.
398 findings in 283 papers from 1985 to 2026, 62 of them since April 2026
Independent labs found the same change in mice and people. 122 independent labs in 34 countries; 45 trials, 6 about aging, 21 with no results posted.
“Among participants with a history of migraine, randomization to E-only MHT was not associated with more severe headache at 1 year (adjusted odds ratio [aOR] = 1.14, 95% confidence interval [CI]: 0.90-1.44)”
12 of its findings point the other way.
- 122 independent labs in 34 countries
- 12 findings against
- 45 trials, 6 about aging, 21 with no results posted
- Funders: National Institutes of Health and others
- 20 of 214 findings with company ties
- 2 of 45 trials sponsored by its developers
- Human trial13
- Humans104
- Animals70
- Cells5
- In silico4
Studies in people
See all 6 studies of estrogen in people6 studies gave estrogen to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on headache severityaOR 1.14, 95% CI 0.90-1.44 | Randomized trial1 year | 22,876 peopleWomenaverage age 64 yearsOlder adults; Postmenopausal women; in participants with a history of migraine | Headache, Jul 8, 2026 |
| Randomized trialaverage 15-year follow-up | WomenPostmenopausal women; postmenopausal women | Maturitas, Feb 11, 2026 | |
down: Decreases cervical dysplasia>90% resolution | Trial4–6 months | 800 peopleWomenaged 40 and olderMidlife adults; Older adults; Postmenopausal women; Patient cohorts | ENDO 2025 abstract, Oct 22, 2025 |
| Trial4 months | WomenpostmenopausalPostmenopausal women; postmenopausal women with at least one moderate-to-severe GSM complaint | Medicina (Kaunas, Lithuania), Dec 30, 2023 | |
up: Improves recognition memory down: Impairs perceptual identification | Randomized trial4 weeks | 6 peopleWomenPostmenopausal women | Hormones and behavior, Feb 1, 2004 |
What did studies of estrogen find?
215Studies of estrogen measured 215 outcomes; the most studied are genitourinary syndrome of menopause (8 studies), apoptosis (7) and cardiovascular disease (6).
Genitourinary syndrome of menopause
downin humans8
8 studies
Genitourinary syndrome of menopause
downin humans8
Estrogen decreases genitourinary syndrome of menopause in humans (postmenopausal women with at least one moderate-to-severe GSM complaint).
“CO2L, RF, and ET significantly improved GSM concerning the vulvar vestibule at the 4 months follow-up.”
Human trialpostmenopausal women with at least one moderate-to-severe GSM complaintvulvar vestibule4 monthsfemales
Medicina (Kaunas, Lithuania)
Estrogen decreases genitourinary syndrome of menopause in genitourinary syndrome of menopause.
“Local estrogen remains supported by a comparatively mature evidence base, whereas energy-based and regenerative strategies show biological and clinical signals but greater heterogeneity and uncertainty.”
Reviewin genitourinary syndrome of menopauselocal
International Journal of Research Publications
Estrogen decreases genitourinary syndrome of menopause in humans (for genitourinary syndrome of menopause in patients with cancer).
“Vaginal estrogen is effective for genitourinary syndrome of menopause, is appropriate in most gynecologic cancers”
Reviewfor genitourinary syndrome of menopause in patients with cancervaginal
Menopause Management in Patients With Cancer
Obstetrics and gynecology
Estrogen decreases genitourinary syndrome of menopause in humans.
“Hormonal therapies – local estrogen, ospemifene, and intravaginal dehydroepiandrosterone (DHEA) – partially restore prevalence and reduce symptom burden”
Review
Obstetrics and gynecology.
Estrogen decreases genitourinary syndrome of menopause in survivors of hormone-sensitive cancer with genitourinary syndrome of menopause.
“low-dose vaginal estrogen provides significant symptom relief and efficacy in easing genitourinary symptoms and reducing urinary tract infections with minimal systemic absorption.”
Reviewin survivors of hormone-sensitive cancer with genitourinary syndrome of menopauselow-dose vaginalfemales
Genitourinary syndrome of menopause in women with cancer - a narrative review
Maturitas
Estrogen decreases genitourinary syndrome of menopause in humans (moderate to severe genitourinary syndrome of menopause).
“For moderate to severe GSM, low-dose vaginal estrogen, vaginal DHEA, and ospemifene are all effective FDA-approved options.”
Reviewmoderate to severe genitourinary syndrome of menopause
Case-Based Perspectives on the Management of Genitourinary Syndrome of Menopause
Clinics and practice
Estrogen decreases genitourinary syndrome of menopause in humans.
“While there are various treatment options, the most effective one is low-dose topical estrogen therapy.”
Reviewtopicallow-dosefemales
Cureus
Estrogen decreases genitourinary syndrome of menopause in humans (postmenopausal women).
“The prescription options have proven efficacy and safety”
Reviewpostmenopausal womenfemales
Genitourinary Syndrome of Menopause
Journal of midwifery & women's health
Apoptosis
downin reviews4downin humans1downin mice1downin mouse cells1+1
7 studies
Apoptosis
downin reviews4downin humans1downin mice1downin mouse cells1+1
Estrogen inhibits apoptosis.
“reducing the production of reactive oxygen species in the electron transport chain, inhibiting apoptosis, and regulating mitochondrial DNA content”
Review
Aging advances
Estrogen decreases apoptosis in mouse cells (D-gal-treated cells).
“Estrogen and the AQP4 inhibitor TGN020 both reduced the apoptosis rate and AQP4 expression.”
CellsD-gal-treated cellsprimary spiral ganglion cell
Preprint
Estrogen inhibits apoptosis in mice (ovariectomized C57BL/6J mice).
“Estrogen inhibited apoptosis of cochlear spiral ganglion cells in aged C57BL/6J mice by downregulating AQP4”
Animalsovariectomized C57BL/6J micecochlear spiral ganglion cell1 or 2 months
Preprint
Estrogen decreases apoptosis.
“oestrogen can effectively alleviate IVDD development by inhibiting the apoptosis of IVD cells”
Reviewintervertebral disc cell
Intervertebral disc ageing and degeneration: The antiapoptotic effect of oestrogen
Ageing research reviews
Estrogen prevents apoptosis in humans (estrogen deficiency).
“Evidence is accumulating that estrogen deficiency induces apoptosis in skeletal muscle contributing to loss of mass and thus strength.”
Reviewestrogen deficiencyskeletal musclefemales
Aging of the musculoskeletal system: How the loss of estrogen impacts muscle strength
Bone
Estrogen prevents apoptosis.
“Basic studies have demonstrated that estrogen treatment prevents apoptosis and necrosis of cardiac and endothelial cells.”
Review
Estrogen and the cardiovascular system
Pharmacology & therapeutics
Estrogen induces apoptosis in cells with wild-type ERalpha.
“a polymeric form of estrogen that is not capable of stimulating the nuclear-initiated actions of ERalpha was as effective as 17beta-estradiol in inducing osteoclast apoptosis”
Cellsin cells with wild-type ERalpha
Molecular endocrinology (Baltimore, Md.)
Estrogen inhibits apoptosis.
“gonadotropins, estrogens, growth hormone, growth factors (IGFI, EGF/TGF-alpha, basic FGF), cytokine (interleukin-1 beta) and nitric oxide act in concert to ensure the survival of preovulatory follicles”
Reviewovary
Recent progress in hormone research
Cardiovascular disease
downin humans5downin reviews1
6 studies
Cardiovascular disease
downin humans5downin reviews1
Estrogen protects against cardiovascular disease in humans (initiated before the age of 60).
“demonstrated the protective role of estrogen in cardiovascular disease (CVD) and bone health, particularly when initiated before the age of 60.”
Reviewinitiated before the age of 60
Management of menopausal hormone therapy
Current opinion in obstetrics & gynecology
Estrogen protects against cardiovascular disease in humans.
“Estrogen confers cardioprotective effects via nitric oxide (NO)-mediated vasodilation and antioxidant pathways.”
Review
Reviews in cardiovascular medicine
Estrogen protects against cardiovascular disease in humans.
“Estrogen provides a protective effect against heart disease in women.”
Reviewfemales
Menopause and women's cardiovascular health: is it really an obvious relationship?
Archives of medical science : AMS
Estrogen protects against cardiovascular disease in humans (before menopause).
“The vasculoprotective role of estrogens are well established before menopause, but the consequences of their abrupt decline on the cardiovascular risk at menopause remain debated.”
Reviewbefore menopause
Estrogen Receptor and Vascular Aging
Frontiers in aging
Estrogen protects against cardiovascular disease.
“Most of these studies suggested that endogenous estrogen confers cardiovascular protective and anti-inflammatory effects.”
Review
Current research in physiology
Estrogen protects against cardiovascular disease in humans.
“Premenopausal women have a lower incidence of cardiovascular disease, which may partly be due to a protective effect of estrogen on endothelial function”
Reviewfemales
Journal of the American Heart Association
Inflammation
downin humans2downin rats2downin mice1upin reviews1
6 studies
Inflammation
downin humans2downin rats2downin mice1upin reviews1
Estrogen decreases inflammation in rats (through ER).
“Estrogen replacement therapy appears to alleviate depressive-like behaviors by reducing brain inflammation and supporting the brain's adaptive capacities through ER.”
Animalsthrough ERbrainfemales
Current issues in molecular biology
Estrogen decreases inflammation in ovariectomized and lead-exposed rats.
“The observed biochemical and histological perturbations were attenuated by HRT.”
Animalsin ovariectomized and lead-exposed ratsprefrontal cortex28 daysfemalesn = 30
Current research in toxicology
Estrogen decreases inflammation in humans (postmenopausal women).
“Estrogen prevents dementia by augmenting Hippocampal and prefrontal cortex function, reducing neuroinflammation”
Reviewpostmenopausal womenbrainfemales
Cureus
Estrogen inhibits inflammation in ovariectomized aged mice.
“VET reverses age-associated upregulation of inflammatory genes and pathways”
Animalsin ovariectomized aged micebladderfemales
Urogynecology (Philadelphia, Pa.)
Estrogen decreases inflammation in humans.
“Estrogens have a protective effect on skeletal muscle by attenuating inflammation;”
Reviewskeletal muscle
Sex Differences in Muscle Wasting
Advances in experimental medicine and biology
Estrogen increases inflammation in some settings.
“in some settings estrogen can have pro-inflammatory effects.”
Reviewin some settings
The effects of estrogen in ischemic stroke
Translational stroke research
Oxidative stress and ROS signaling
downin mice2downin humans1downin mouse cells1downin rats1+1
6 studies
Oxidative stress and ROS signaling
downin mice2downin humans1downin mouse cells1downin rats1+1
Estrogen decreases oxidative stress and ROS signaling in mice (aging).
“treatment with estrogen (a) significantly reduced the formation of TAs; (b) reduced oxidative stress”
Animalsagingdrinking waterskeletal musclemales
Estrogens and Antioxidants Prevent the Formation of Tubular Aggregates in Aging Male Mice
International journal of molecular sciences
Estrogen decreases oxidative stress and ROS signaling.
“In the mitochondria, estrogen functions by reducing the production of reactive oxygen species in the electron transport chain”
Review
Aging advances
Estrogen decreases oxidative stress and ROS signaling in ovariectomized and lead-exposed rats.
“The observed biochemical and histological perturbations were attenuated by HRT.”
Animalsin ovariectomized and lead-exposed ratsprefrontal cortex28 daysfemalesn = 30
Current research in toxicology
Estrogen protects against oxidative stress and ROS signaling in humans.
“age-related estrogen deficiency, taking into account their antioxidant properties, is considered as one of the triggers for this condition development”
Review
Age-related menopause and carbonyl stress
Advances in gerontology = Uspekhi gerontologii
Estrogen decreases oxidative stress and ROS signaling in mouse cells (LPS-induced in bEnd.3 brain endothelial cells).
“the lipopolysaccharide (10 ng/mL)-induced increases of hepcidin mRNA and protein levels, the number of Prussian blue-positive cells, and free radicals were reduced after estrogen treatment”
CellsLPS-induced in bEnd.3 brain endothelial cellsbrain endothelial cells
Neurobiology of aging
Estrogen decreases oxidative stress and ROS signaling in mice (gonadectomy).
“Exactly the same changes in oxidative stress were acutely reproduced by gonadectomy in 5-month-old females or males and reversed by estrogens or androgens in vivo as well as in vitro.”
Animalsgonadectomy
Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids
The Journal of biological chemistry
Cellular senescence
no changein human cells1downin humans1downin mice1downin rat cells1+1
5 studies
Cellular senescence
no changein human cells1downin humans1downin mice1downin rat cells1+1
Estrogen decreases cellular senescence in pelvic floor connective tissue.
“mitigation of cellular senescence”
Reviewin pelvic floor connective tissue
Frontiers in immunology
Estrogen prevents cellular senescence in male mice on a ketogenic diet.
“the increases in p53, p21, cellular senescence, MnSOD acetylation, and oxidative stress in male mice on a KD were all prevented by estrogen treatment”
Animalsin male mice on a ketogenic dietmales
Cell reports
Estrogen showed no clear effect on cellular senescence in human cells (HRASG12V expression).
“We experimentally confirmed the inability of HRASG12V-expressing EnSCs to bypass senescence and resume proliferation, even upon estrogen stimulation.”
CellsHRASG12V expressionendometrial stroma
International journal of molecular sciences
Estrogen inhibits cellular senescence.
“estrogen protects against genotoxic insult and inhibits senescence regulatory proteins”
Review
Evidence of sex differences in cellular senescence
Neurobiology of aging
Estrogen decreases cellular senescence in BMSCs from OVX rats.
“BMSCs from the OVX rats displayed increased senescence and weaker SATB2 expression, stemness, and osteogenic differentiation, while estrogen could rescue these phenotypes.”
Cellsin BMSCs from OVX rats
Journal of cellular physiology
Cognitive function
upin mice2upin humans1upin reviews1
4 studies
Cognitive function
upin mice2upin humans1upin reviews1
Estrogen is linked with better cognitive function in humans (non-depressed older women) (effect size = .61, p = .02).
“Within the non-depressed participants, higher CLEE was associated with improved delayed recall”
Humansnon-depressed older womenfemalesn = 71
Journal of geriatric psychiatry and neurology
Estrogen improves cognitive function.
“Estrogen was found to enhance synaptic plasticity, dendritic spine density, neurogenesis, and hippocampal-dependent cognition through genomic and non-genomic mechanisms.”
Review
The interplay between sex hormones and brain plasticity across the lifespan
The Egyptian Journal of Internal Medicine
Estrogen improves cognitive function in mice (sevoflurane-exposed C57BL/6 mice).
“increasing synaptic vesicle density and neuronal firing frequency, and improving cognitive function.”
Animalssevoflurane-exposed C57BL/6 micefemales
Estrogen improves sevoflurane-induced cognitive dysfunction by regulating synaptic zinc homeostasis
Molecular medicine (Cambridge, Mass.)
Estrogen improves cognitive function in mice after surgery and anesthesia.
“their cognitive function improved after estrogens supplementation (P < 0.05).”
Animalsafter surgery and anesthesiamales
Behavioural brain research
Bone loss
downin humans1downin mice1downin rats1
3 studies
Bone loss
downin humans1downin mice1downin rats1
Estrogen decreases bone loss in ovariectomized rats.
“Estrogen treatment markedly alleviated OVX-induced bone loss”
Animalsin ovariectomized rats
Biology
Estrogen decreases bone loss in mice (postmenopausal osteoporosis).
“The delivery system significantly reduced bone loss in postmenopausal osteoporotic mice”
Animalspostmenopausal osteoporosisCA-PEOz drug delivery systembone
Materials today. Bio
Estrogen prevents bone loss in women at high risk for osteoporosis.
“For women at high risk for osteoporosis, especially perimenopausal women with low bone density and other risk factors, estrogen or other therapies are available to prevent bone loss.”
Reviewin women at high risk for osteoporosis
Menopause (New York, N.Y.)
Breast cancer
no changein humans3
3 studies
Breast cancer
no changein humans3
Estrogen was not clearly linked with breast cancer in prior pre-eclamptic women.
“whereas estrogen only was not associated with BC risk in prior pre-eclamptic women.”
Humansin prior pre-eclamptic women
The Journal of clinical endocrinology and metabolism
Estrogen was not clearly linked with breast cancer in humans (past long-term use of oestrogen only therapy).
“Past long term use of oestrogen only therapy and past short term (<5 years) use of oestrogen-progestogen were not associated with increased risk.”
Humanspast long-term use of oestrogen only therapyoestrogen only therapylong-term usefemalesn = 457,498
BMJ (Clinical research ed.)
Estrogen showed no clear effect on breast cancer in humans after hysterectomy.
“estrogen-alone therapy after hysterectomy does not increase breast cancer incidence”
Reviewafter hysterectomy
Menopausal hormone therapy and breast cancer: risk and management
Current opinion in obstetrics & gynecology
Mortality
downin humans2no changein humans1HR 0.99
3 studies
Mortality
downin humans2no changein humans1HR 0.99
Estrogen was not clearly linked with mortality in humans (estrogen-only users compared with non-users, matched on age and general practice) (HR 0.99 (95% CI 0.93-1.07)).
“estrogen-only formulation was not associated with any significant changes”
Humansestrogen-only users compared with non-users, matched on age and general practiceestrogen-onlyfemales
BJOG : an international journal of obstetrics and gynaecology
Estrogen decreases mortality in humans after hysterectomy.
“estrogen-alone therapy after hysterectomy does not increase breast cancer incidence and is associated with reduced mortality”
Reviewafter hysterectomy
Menopausal hormone therapy and breast cancer: risk and management
Current opinion in obstetrics & gynecology
Estrogen decreases mortality in humans (early initiation in younger menopausal women).
“consistently show reductions in coronary heart disease and mortality in younger menopausal women.”
Reviewearly initiation in younger menopausal womenfemales
Estrogen rapid effects: a window of opportunity for the aging brain?
Neural regeneration research
Headache severity
no changein humans1
1 study
Headache severity
no changein humans1
Estrogen showed no clear effect on headache severity in participants with a history of migraine (aOR 1.14, 95% CI 0.90-1.44).
“Among participants with a history of migraine, randomization to E-only MHT was not associated with more severe headache at 1 year (adjusted odds ratio [aOR] = 1.14, 95% confidence interval [CI]: 0.90-1.44)”
Human trialin participants with a history of migraineoral1 yearfemales
Combined hormone therapy linked to worsening headaches
Headache
Plasma Alzheimer's biomarker
no changein humans1
1 study
Plasma Alzheimer's biomarker
no changein humans1
Estrogen showed no clear effect on plasma Alzheimer's biomarker in humans (postmenopausal women; compared with placebo).
“did not significantly differ for estrogen alone vs placebo or estrogen plus progestin vs placebo.”
Human trialpostmenopausal women; compared with placeboplasmaaverage 15-year follow-upfemales
Maturitas
Cervical dysplasia
downin humans1
1 study
Cervical dysplasia
downin humans1
Estrogen decreases cervical dysplasia in humans (>90% resolution).
“Over 90% of participants experienced resolution of abnormal cytology within 4–6 months of initiating local estrogen therapy.”
Human triallocal vaginalcervix4–6 monthsfemalesn = 800
ENDO 2025 abstract
Sexual function
upin humans1
1 study
Sexual function
upin humans1
Estrogen improves sexual function in humans (Postmenopausal women; compared with licorice vaginal cream) (Sexual function scores: estrogen 17.14 ± 3.99 to 22.97 ± 5.09; licorice 17.86 ± 4.37 to 20.31 ± 4.63).
“The effect of estrogen vaginal cream on the sexual function of postmenopausal women was greater than licorice vaginal cream.”
Human trialPostmenopausal women; compared with licorice vaginal creamvaginal cream2%2 months follow-upfemalesn = 82
International journal of reproductive biomedicine
Perceptual identification
downin humans1
1 study
Perceptual identification
downin humans1
Estrogen impairs perceptual identification in humans.
“This pattern reversed in perceptual identification with estrogens producing a negative effect and androgens producing a positive effect.”
Human trialfemalesn = 6
Hormones and behavior
All 215Fewer
What is estrogen linked with?
98Studies link estrogen with 98 measures, most often breast cancer (8 studies), venous thromboembolism (5) and Alzheimer's disease (5).
Breast cancer
downin humans4upin humans4RR 0.77
8 studies
Breast cancer
downin humans4upin humans4RR 0.77
Estrogen is linked with a higher risk of breast cancer in humans (adjusting for BMI and menopausal status) (aOR 1.33, 95% CI 1.13-1.57).
“each standard deviation increase in CLEEE was associated with 33% higher BC odds (aOR 1.33, 95% CI 1.13-1.57)”
Humansadjusting for BMI and menopausal status
Breast cancer research and treatment
Estrogen is linked with a lower risk of breast cancer in BRCA1 or BRCA2 carriers, compared with unexposed matched controls (HR 0.37, 95% CI 0.24 to 0.57).
“women who used estrogen alone experienced a statistically significantly decreased risk of breast cancer (hazard ratio = 0.37, 95% CI = 0.24 to 0.57)”
Humansin BRCA1 or BRCA2 carriers, compared with unexposed matched controlsfemalesn = 676
Journal of the National Cancer Institute
Estrogen is linked with a higher risk of breast cancer in humans (postmenopausal).
“In postmenopausal women, higher estrogens and androgens were associated with an increase in breast cancer risk, whereas higher SHBG was inversely associated with risk.”
Humanspostmenopausalfemales
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Estrogen is linked with a higher risk of breast cancer in humans (recent (<5 years) use with long-term use (≥5 years), compared with never use) (adjusted odds ratio 1.15 (95% CI 1.09 to 1.21)).
“oestrogen only therapy and combined oestrogen and progestogen therapy were both associated with increased risks of breast cancer”
Humansrecent (<5 years) use with long-term use (≥5 years), compared with never useoestrogen only therapylong-term use (≥5 years)femalesn = 457,498
BMJ (Clinical research ed.)
Estrogen lowers the risk of breast cancer in patients who have undergone hysterectomy at population risk for breast cancer (3.6% vs 4.7% (RR 0.77, 95% CI 0.65-0.91)).
“relative risk 0.77; 95% CI, 0.65-0.91, P=.002”
Reviewin patients who have undergone hysterectomy at population risk for breast cancer
Menopausal Estrogen Therapy and Risk of Breast Cancer
Obstetrics and gynecology
Estrogen raises the risk of breast cancer in observational studies.
“Estrogen-only therapy (ET) shows a modest risk increase in observational studies, but RCT data (e.g., WHI) suggest reduced incidence and mortality.”
Reviewin observational studies
MENOPAUSAL HORMONE THERAPY AND BREAST CANCER RISK
International Journal of Innovative Technologies in Social Science
Estrogen lowers the risk of breast cancer in menopause.
“estrogen-alone therapy has been linked to reductions in both breast cancer incidence and mortality.”
Reviewin menopause
Menopausal hormone therapy and breast cancer: Balancing risks and benefits
Maturitas
Estrogen is associated with breast cancer in humans.
“Oestrogen only therapy in women who have undergone hysterectomy appears associated with a lower risk of breast cancer than combined oestrogen and progestogen MHT.”
Reviewwomen who have undergone hysterectomy; compared with combined estrogen and progestogen menopausal hormone treatmentfemales
Menopausal hormone treatment and breast cancer
The lancet. Diabetes & endocrinology
Venous thromboembolism
upin humans5HR 1.62
5 studies
Venous thromboembolism
upin humans5HR 1.62
Estrogen is associated with venous thromboembolism in humans (British-South Asian women).
“VTE prevalence increased with obesity, hypertension, dyslipidemia, chronic kidney disease, estrogen use, and in the presence of FVL.”
HumansBritish-South Asian womenfemalesn = 20,048
iScience
Estrogen raises the risk of venous thromboembolism in humans (hepatic first-pass metabolism).
“oral estrogens undergo hepatic first-pass metabolism, elevating venous thromboembolism risk”
Reviewhepatic first-pass metabolismoralfemales
Menopausal Hormone Therapy and Cardiovascular Risk: Current Evidence and Treatment Recommendations
Cardiology in review
Estrogen raises the risk of venous thromboembolism in humans (HR 1.62, 95% CI 1.41–1.86).
“Venous thromboembolism risk was significantly elevated with oral estrogen (HR 1.62; 95% CI 1.41–1.86)”
Revieworalfemales
Journal of medical & health sciences review.
Estrogen raises the risk of venous thromboembolism in humans.
“Clinical guidelines recognise oral oestrogen as a VTE risk factor”
Revieworal
JRSM open
Estrogen raises the risk of venous thromboembolism in humans.
“Exogenous estrogen, commonly in the form of combined hormonal contraceptives and menopausal hormone therapies, is associated with changes in coagulation proteins leading to increased risk of venous thromboembolism (VTE).”
Reviewcombined hormonal contraceptives and menopausal hormone therapies
Clinics in laboratory medicine
Alzheimer's disease
downin humans4upin humans1HR 1.081
5 studies
Alzheimer's disease
downin humans4upin humans1HR 1.081
Estrogen is linked with a higher risk of Alzheimer's disease in humans during menopause (HR 1.081, 95% CI 1.03–1.134).
“TIB (HR 1.041, 95% confidence interval (CI) 1.01-1.072) and oral estrogen alone (HR 1.081, 95% CI 1.03-1.134) were associated with a higher risk of AD dementia.”
Humansduring menopauseoral estrogen alonefemales
Frontiers in aging neuroscience
Estrogen lowers the risk of Alzheimer's disease in humans.
“Research shows that a longer reproductive lifespan, or a greater cumulative estrogen exposure, is associated with slower cognitive decline and reduced AD risk.”
Reviewfemales
International journal of high school research
Estrogen lowers the risk of Alzheimer's disease in humans (initiated within ~five years of menopause).
“oral estrogen-only therapy initiated within ~five years of menopause is most consistently associated with reduced AD risk”
Reviewinitiated within ~five years of menopauseoral
Journal of High School Science
Estrogen lowers the risk of Alzheimer's disease in postmenopausal women.
“Estrogen reduces the risk of AD in postmenopausal women.”
Reviewin postmenopausal womenfemales
Journal of Alzheimer's disease reports
Estrogen lowers the risk of Alzheimer's disease in brain imaging studies.
“In contrast, brain imaging studies provide encouraging evidence for positive associations between greater cumulative lifetime estrogen exposure and lower AD risk in women”
Reviewin brain imaging studiesfemales
Frontiers in aging neuroscience
Cardiovascular disease
downin humans4
4 studies
Cardiovascular disease
downin humans4
Estrogen lowers the risk of cardiovascular disease in humans.
“Exposure to endogenous oestrogen during the reproductive years provides women with protection against cardiovascular disease”
Reviewfemales
Menopause: a cardiometabolic transition
The lancet. Diabetes & endocrinology
Estrogen is associated with cardiovascular disease in humans.
“incidence of cardiovascular disease in postmenopausal women is significantly higher than that in men”
Reviewcardiovascular systemfemales
Protective Effects of Estrogen on Cardiovascular Disease Mediated by Oxidative Stress
Oxidative medicine and cellular longevity
Estrogen lowers the risk of cardiovascular disease in humans.
“its many beneficial effects on cardiovascular health are lost whereby the age-related risk of cardiovascular disease is accelerated”
Reviewfemales
The Journal of physiology
Estrogen lowers the risk of cardiovascular disease in humans.
“suggests that estrogens play a protective role against cardiovascular disease and that this role is also modified by ageing”
Reviewfemales
Role of miRNA in the Regulatory Mechanisms of Estrogens in Cardiovascular Ageing
Oxidative medicine and cellular longevity
Coronary artery disease
downin humans3RR 0.78
3 studies
Coronary artery disease
downin humans3RR 0.78
Estrogen lowers the risk of coronary artery disease in humans (Initiation within 10 years of menopause; versus placebo) (RR 0.78; 95% CI 0.66-0.92).
“estrogen alone reduced coronary heart disease (CHD) risk (RR 0.78; 95% CI 0.66-0.92)”
ReviewInitiation within 10 years of menopause; versus placebofemales
AHA Scientific Sessions 2026 abstract
Estrogen is associated with coronary artery disease in humans (compared with nonuse).
“Vaginal estrogen use is associated with lower risk for coronary heart disease (CHD)”
Reviewcompared with nonusevaginal
Does vaginal estrogen use increase the risk for adverse cardiovascular outcomes?
The Journal of family practice
Estrogen lowers the risk of coronary artery disease in humans (early initiation in younger menopausal women).
“consistently show reductions in coronary heart disease and mortality in younger menopausal women.”
Reviewearly initiation in younger menopausal womenfemales
Estrogen rapid effects: a window of opportunity for the aging brain?
Neural regeneration research
Migraine
upin humans2downin humans1
3 studies
Migraine
upin humans2downin humans1
Estrogen is associated with migraine in humans (early perimenopause, with anovulatory cycles).
“Hyperestrogenism during early perimenopause, coupled with anovulatory cycles, is associated with an increased frequency and severity of migraine attacks”
Reviewearly perimenopause, with anovulatory cyclesfemales
Perimenopausal migraine: a narrative review
Climacteric : the journal of the International Menopause Society
Estrogen is associated with migraine in humans (reproductive lifespan).
“Its occurrence and clinical expression are closely associated with hormonal fluctuations throughout the reproductive lifespan, particularly those involving estrogen.”
Reviewreproductive lifespanfemales
Migraine across the menopausal transition: a scoping review
Preprint
Estrogen is associated with migraine in humans.
“In women, migraine remissions are associated with stable and critical oestrogen levels.”
Reviewfemales
Menopause hormone therapy, migraines, and thromboembolism
Best practice & research. Clinical obstetrics & gynaecology
Mortality
upin humans2downin humans1OR 0.2–0.4
3 studies
Mortality
upin humans2downin humans1OR 0.2–0.4
Estrogen is linked with a lower risk of mortality in women with recurrent urinary tract infection (OR 0.2-0.4 across age groups).
“Mortality increased with age in both groups but remained lower among estrogen recipients at 0.3%-3.9% vs 0.8%-9.6% in nonrecipients (OR 0.2-0.4 across age groups).”
Humansin women with recurrent urinary tract infectionfemales
Urology
Estrogen is associated with mortality in humans (before accounting for discontinuation) (aHR 4.73, 1.22 to 18.32).
“Use of systemic estrogens alone is associated with increased COVID-19 mortality among older women (aHR 4.73, 1.22 to 18.32)”
Humansbefore accounting for discontinuationfemales
BMC medicine
Estrogen is linked with a higher risk of mortality in humans (HR, 1.02; 95% CI 1.00-1.04).
“unopposed cumulative E exposure (HR, 1.02; 95% CI 1.00-1.04) were significantly harmful for all-cause mortality.”
Humansfemales
Fertility and sterility
Cognitive function
mixedin humans1upin humans1mixedin reviews1
3 studies
Cognitive function
mixedin humans1upin humans1mixedin reviews1
Estrogen is associated with cognitive function in humans.
“evidence for shared genetic architecture between lifetime estrogen exposure and AD-related cognitive decline”
Humansn = 33,918
medRxiv : the preprint server for health sciencesPreprint
Estrogen is associated with cognitive function in humans.
“oestrogen directly impacted performance”
Humansn = 121
Research SquarePreprint
Estrogen is associated with cognitive function.
“estrogen modulates cognition in animal models”
Reviewfemales
Current psychiatry reports
Glaucoma
downin humans1upin humans1OR 1.33
2 studies
Glaucoma
downin humans1upin humans1OR 1.33
Estrogen is linked with a lower risk of glaucoma in humans (P < 0.001).
“long-term estrogen use (n = 39 202) showed decreased risk of glaucoma diagnosis (P < 0.001).”
Humanslong-termn = 39,202
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
Estrogen is linked with a higher risk of glaucoma in humans (adjusted OR, 1.33 [95% CI, 1.17-1.52]).
“The risk was found in estrogen users (adjusted OR, 1.33 [95% CI, 1.17-1.52])”
Humansfemales
Acta ophthalmologica
Osteoporotic fractures
downin humans1upin humans1
2 studies
Osteoporotic fractures
downin humans1upin humans1
Estrogen lowers the risk of osteoporotic fractures in postmenopausal women.
“estrogens reduce the risk of osteoporotic-related fractures, including hip and vertebral and nonvertebral fractures, in postmenopausal women.”
Reviewin postmenopausal womenestrogensfemales
Efficacy and safety of estrogen therapy for prevention of osteoporosis in postmenopausal women
Women's health (London, England)
Estrogen is associated with osteoporotic fractures in postmenopausal women.
“estrogen use and vitamin D supplements were significantly associated with osteoporotic fracture in postmenopausal women.”
Reviewin postmenopausal women
Predictors of osteoporotic fracture in postmenopausal women: a meta-analysis
Journal of orthopaedic surgery and research
All 98Fewer
What acts on estrogen?
1Studies name Parvalbumin-positive interneuron as acting on estrogen.
Parvalbumin-positive interneuron
upin humans1
1 study
Parvalbumin-positive interneuron
upin humans1
parvalbumin-positive interneuron increases estrogen in humans.
“Parvalbumin-positive (PV) interneurons enhance synaptic activity-dependent brain-derived estradiol (BDE2) synthesis in a sex-specific manner”
Reviewbrain
Alzheimer's & dementia : the journal of the Alzheimer's Association
Has estrogen been tested in people?
6 of 45 about agingYes: 13 trials and 105 observational studies in people have been published, and 43 trials are registered.
About aging
The Anabolic Effects of Estrogen on Skeletal Muscles
Completed
Phase 2/3Completed
Phase 2Completed
Phase 3Completed
Effects of Estrogen Therapy on Lipid Metabolism and Insulin Sensitivity in Hypogonadal Women
Completed
Early phase 1Recruiting
Every condition in trials
Phase 4Results posted3 trials
Phase 4Completed2 trials
Phase 4Completed2 trials
Phase 4Completed2 trials
Phase 4Terminated2 trials
Phase 4Terminated2 trials
40 of 50Fewer
Stopped
NCT00203996TerminatedObstructive sleep apnea
Did not meet target patient accrual goals
Trial sponsors
Company1 trialPhase 465 people
Company1 trialPhase 2150 people
2 trialsPhase 41,285 people
1 trialPhase 4400 people
Peking Union Medical College Hospital
1 trialPhase 4200 people
1 trialPhase 4148 people
1 trialPhase 4120 people
1 trialPhase 490 people
Funding
142 grants since 2016National Institute on Aging$62MNational Institute of Diabetes and Digestive and Kidney Diseases$23.8MNational Heart, Lung, and Blood Institute$21.2M
National Heart, Lung, and Blood InstituteTufts University Boston$55.1K2025–2027
National Institute on AgingHumboldt State University$268K2026–2029
Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans
US Department of Veterans AffairsSoutheast Louisiana Veterans Health Care2021–2026
National Institute of Neurological Disorders and StrokeSpelman College$226K2022–2027
National Heart, Lung, and Blood InstituteDes Moines Univ Osteopathic Medical Ctr$536K2026–2029
The sexually dimorphic role of smooth muscle cell estrogen receptor alpha in vascular aging
National Heart, Lung, and Blood InstituteTufts Medical Center$681K2022–2027
National Institute on AgingUniversity of Colorado, Denver$190K2026–2031
Role of Estrogen Related Receptors in Age Related Kidney Disease
National Institute of Diabetes and Digestive and Kidney DiseasesGeorgetown University$754K2020–2029
National Institute of Allergy and Infectious DiseasesOregon Health & Science University$177K2024–2027
Modulation of Corneal Endothelial Mitochondrial Activity and Dysfunction by Estrogen
National Eye InstituteTrustees of Indiana University$423K2024–2028
How this record changed
Summary rewritten as its findings changed.
As it read before
Estrogen reduces oxidative stress in mice in studies from independent labs; one study also reports improved store-operated calcium entry in aging male mouse muscle. Human studies link estrogen with higher breast cancer risk after menopause but lower risk in BRCA1/2 carriers; mortality associations point both ways. Some papers disclose company ties.
Summary rewritten as its findings changed.
As it read before
Estrogen reduces oxidative stress in mice, a result reproduced by independent labs; a preprint reports protection against age-related hearing loss in ovariectomized mice. Independent labs also link estrogen use with higher breast cancer risk in women, whereas a study links it with lower risk in BRCA1 or BRCA2 carriers. Some papers declare company ties.
Summary rewritten as its findings changed.
As it read before
Estrogen reduces senescence in rat cells and oxidative stress in mice across independent labs; human cohorts link use with higher breast cancer risk in postmenopausal women but lower risk in BRCA1/2 carriers. Four registered trials concern aging; across uses, 21 ended over a year ago without posted results. Some authors have company affiliations; two trials have company sponsors.
Summary rewritten as its findings changed.
As it read before
One rat study shows that estrogen reduces bone loss and improves trabecular bone microarchitecture in ovariectomized rats. A human preprint associates vaginal estrogen use for at least six weeks with urinary lactobacilli in postmenopausal women.
Summary written from the findings.